Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)

Cancer shared this article with you from Inoreader Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC) Via MedWorm Cancer & Oncology Clinical Trials Condition:   Lung Cancer, Nonsmall Cell Interventions:   Drug: Pembrolizumab;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Pemetrexed Sponsor:   McGill University Health Centre/Research Institute of the McGill University Health Centre Not yet recruiting (Source: ClinicalTrials.gov) View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.